An investigation on behalf of investors in Keryx Biopharmaceuticals (NASDAQ:KERX) shares over potential wrongdoing at Keryx Biopharmaceuticals was announced and NASDAQ:KERX stockholders should contact the Shareholders Foundation.
San Diego, CA -- (SBWIRE) -- 03/15/2017 -- Certain directors of Keryx Biopharmaceuticals are under investigation over potential wrongdoing. The investigation was announced for current long-term investors in NASDAQ:KERX shares over potential breaches of fiduciary duties by certain directors at Keryx Biopharmaceuticals.
Investors who purchased shares of Keryx Biopharmaceuticals (NASDAQ:KERX) and currently hold any of those NASDAQ:KERX shares have certain options and should contact the Shareholders Foundation at email@example.com or call 858-779-1554.
The investigation by a law firm concerns whether certain Keryx Biopharmaceuticals directors breached their fiduciary duties and caused damage to the company and its shareholders.
Keryx Biopharmaceuticals reported that its annual total Revenue rose from $7.00 million in 2013 to $13.68 million in 2015 and that its Net Loss increased from $46.73 million in 2013 to $123.14 million in 2015.
Shares of Keryx Biopharmaceuticals (NASDAQ:KERX) declined from $18.19 per share in August 2014 to as low as $3.29 per share in January 2016.
Those who purchased shares of Keryx Biopharmaceuticals (NASDAQ:KERX), have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North - Suite 423
92108 San Diego